Neal Bhatia, MD

Articles

Atopic Dermatitis Treatment Biological Targets

Raj Chovatiya, MD, PhD, MSCI;Neal Bhatia, MD

December 13th 2022

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

Raj Chovatiya, MD, PhD, MSCI;Neal Bhatia, MD

December 13th 2022

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.

Gaps in Management of AD SOC Patients

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 23rd 2022

Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.

AD Patient Case: FST III

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 23rd 2022

Three dermatologists discuss the case of an 18-year-old patient with AD who is exploring nonsteroidal options to manage his disease.

Cost and Access to AD Treatments

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 16th 2022

Drs Noor and Bhatia have a conversation about cost and financial assistance from pharmaceutical companies.

AD Patient Case: FST V

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 16th 2022

Drs Bhatia and Lamb discuss the case of a 12-year-old child with asthma and how they would manage his disease.

AD Patient Case: FST I

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 9th 2022

Experts discuss the case of a 4-year-old girl with lighter skin and treatment options for a young child.

Setting Expectations About Treatments With Patients

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 9th 2022

Three experts emphasize the importance of setting expectations for AD treatment with patients.

Mechanism of Action and AD Treatment Selection in Patients With Skin of Color

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 2nd 2022

Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.

Approaching Treatment Selection in AD

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

August 2nd 2022

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Communication About Adverse Effects of Atopic Dermatitis Treatments

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

July 26th 2022

Drs Noor and Lamb highlight the importance of frank discussion of adverse effects of atopic dermatitis treatments with patients.

Building Trust With Patients With Atopic Dermatitis

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

July 26th 2022

Drs Bhatia, Lamb and Noor talk about the importance of building trust with patients and highlight topics to discuss with patients and parents.

Increasing Awareness of Advances in AD Management with Physicians and Patients

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

July 19th 2022

Dermatology experts discuss strategies to increase awareness of advances in AD in patients with SOC.

Overview of Atopic Dermatitis in Patients of Skin of Color

Neal Bhatia, MD;Angela Lamb, MD;Omar Noor, MD, FAAD

July 19th 2022

Drs. Neal Bhatia and Angela Lamb provide an overview of atopic dermatitis and its prevalence in patients with skin of color (SOC).

JAK Inhibitors: Non-Responders and Safety Considerations

James Q. Del Rosso, DO;Neal Bhatia, MD

February 28th 2022

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

Oral JAK Inhibitors for Atopic Dermatitis

James Q. Del Rosso, DO;Neal Bhatia, MD

February 21st 2022

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

Topical JAK Inhibitors for Atopic Dermatitis

James Q. Del Rosso, DO;Neal Bhatia, MD

February 14th 2022

A review of topical JAK inhibitor ruxolitinib.

JAK Inhibitors: An Overview

James Q. Del Rosso, DO;Neal Bhatia, MD

February 7th 2022

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.